News

Zacks.com on MSN18h
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...
Zacks.com on MSN22h
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Madrigal stock jumps as patent protection for MASH treatment extended
The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click ...
Investor's Business Daily on MSN19h
Madrigal Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark
Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.
InvestorsHub on MSN1d
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...
Santé log1d
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book ...